Articles related to GUIDELINES/RECOMMENDATIONS

Leveraging Clinical Decision Support Tools for Optimized Cancer Care Delivery For oncologists, navigating the complicated world of cancer treatment can be a challenging undertaking. Clinical decision support tools like Flatiron Assist may be able to help as they offer better instructions and make it possible to administer high-quality care. Key Points: “Given the increasing complexity of the oncology treatment landscape, this study found that utilizing a customizable CDS tool like FA provides an opportunity for custom preferred pathways to optimize cancer treatment ordering in cases where NCCN guidelines are less clear and that regardless of the path­way in place, providers order preferred treatment options a large majority of the time.” Study Conclusion

Unveiling USPSTF’s New Recommendation for Breast Cancer Screenings The US Preventive Services Task Force (USPSTF) has issued a notable change in breast cancer screening guidelines, shedding light on the growing concern of breast cancer morbidity in the United States. This recommendation has profound implications for early detection and potential reduction in mortality rates.

Insomnia is often underrecognized and undertreated in primary care settings. A panel of experts convened by Haymarket Medical Education emphasizes the importance of considering comorbid medical and psychiatric illnesses in patients with insomnia and recommends proactive screening and personalized treatment strategies. As a psychiatrist, neurologist, or other sleep disorder professional, you may often be on the front lines of managing insomnia, a condition that is increasingly prevalent yet remains underrecognized in primary care settings. A recent report by a panel of experts provides crucial insights and recommendations to enhance our approach to this pervasive sleep disorder:

Dive into the essence of AANA’s updated guidelines for obstetric anesthesia and analgesia as we spotlight its focus on health equity and safety in maternal care. Commencing with the unveiling of the revised practice guidelines for obstetric anesthesia and analgesia, the American Association of Nurse Anesthesiology (AANA) has emphasized enhancing patient care and safety. Interestingly, these updates also strive to tackle the critical issue of enduring health disparities in the United States. The AANA firmly believes in the power of certified registered nurse anesthetists (CRNAs) to help curb maternal mortality rates. The primary strategy focuses on mitigating racial and ethnic imbalances in pregnancy-related deaths. Beth Ann Clayton, DNP, CRNA, FAANA, FAAN, the key subject matter expert behind the revisions, underscores these inequalities as significant barriers to optimal maternal care. Using an evidence-based process, the AANA revised the guidelines, paying careful attention to current research. They’ve prioritized enhancing the readability of the content, updating the quality of references, and broadening their scope to encompass the most recent recommendations on obstetric analgesia and anesthesia care. The notable alterations include the broadening of analgesia and anesthesia considerations for labor and delivery. This expansion encompasses inhalation analgesia, neuraxial analgesia, general anesthesia, and an updated […]

Dive into this CME program to grasp the latest C. difficile guidelines and implement treatment strategies effectively. This interactive CME program focuses on Clostridioides difficile, or C. difficile. As you know, this bacterium causes severe GI disturbances. Alarmingly, it impacts half a million Americans annually and burdens the healthcare system. Who is this for? Infectious disease physicians, gastroenterologists, hospitalists, intensivists, and all HCPs managing patients with C. difficile infection (CDI) will benefit greatly. Initially, the program offers a comprehensive review of CDI. It presents the epidemiology and pinpoints key risk factors. Moreover, it explains the underlying pathophysiology and outlines clinical features. Significantly, it emphasizes the disease’s burden and unveils diagnostic tools, including NAAT, GDH assay, and toxin tests. Following this, the program shifts to treatment strategies for CDI. It details procedures for various severity levels – mild, severe, fulminant, and recurrent. Concurrently, it underlines the common challenges in therapy decision-making. Importantly, it stresses the necessity of adhering to CDI guidelines and presents preventative measures. In the concluding section, participants receive practical patient cases. This allows the application of newfound knowledge directly. Afterward, it wraps up with a summary and a best practice recap. Upon completion, participants will grasp the burden […]

Delve into the changes in the updated Beers criteria and their implications for medication use in older patients. The American Geriatrics Society (AGS) has recently revised the Beers criteria. Significantly, these guidelines advise physicians to be cautious when prescribing medications like warfarin and sodium-glucose cotransporter-2 (SGLT2) inhibitors for patients over 65. Importantly, warfarin is now a drug to avoid in initial therapy for venous thromboembolism or nonvalvular atrial fibrillation unless alternatives are contraindicated or face significant usage barriers. The Beers criteria are organized into five distinct categories. These include potentially inappropriate medications, ones that might be inappropriate for patients with certain conditions, medications requiring careful usage, potential drug-drug interactions, and medications needing renal function-based dosage adjustments. An expert panel sifted through evidence from June 1, 2017, to May 31, 2022, to create these updates. These guidelines apply to patients aged 65 years and older in most care settings in the US, excluding hospice and end-of-life care situations. Among the notable changes since 2019 is the inclusion of warfarin. For older patients using warfarin long-term, continuation might be reasonable if they show well-controlled international normalized ratios and no adverse effects. Additional drugs introduced since 2019 include ticagrelor and SGLT2 inhibitors (use […]